CURE SMA

IL

Focused on the treatment and cure of Spinal Muscular Atrophy through research and support

Active 2016–2026. The register lists this client once for every firm that files on its behalf; all 2 of its records are shown together here.

Filings
55
Filed By
2
Reported In-House
$2,090,000
Reported By Firms
$290,000

These two figures are not added together. A client that lobbies for itself reports its own spending, while firms it retains report what they were paid. Disclosure rules ask the in-house figure to include those payments, but filings do not always do so, and a filing gives no way to tell. Each is shown as reported.

Filings

YearFirmPeriodAmountDoc
2026 CURE SMA 3rd Quarter (July 1 - Sep 30)
3rd Quarter - Report
$75,000
2026 CURE SMA 2nd Quarter (Apr 1 - June 30)
2nd Quarter - Report
$75,000
2026 CURE SMA 1st Quarter (Jan 1 - Mar 31)
1st Quarter - Report
$75,000
2025 CURE SMA 4th Quarter (Oct 1 - Dec 31)
4th Quarter - Report
$75,000
2025 CURE SMA 3rd Quarter (July 1 - Sep 30)
3rd Quarter - Report
$75,000
2025 CURE SMA 2nd Quarter (Apr 1 - June 30)
2nd Quarter - Report
$75,000
2025 CURE SMA 1st Quarter (Jan 1 - Mar 31)
1st Quarter - Report
$75,000
2024 CURE SMA 4th Quarter (Oct 1 - Dec 31)
4th Quarter - Report
$75,000
2024 CURE SMA 3rd Quarter (July 1 - Sep 30)
3rd Quarter - Report
$75,000
2024 CURE SMA 2nd Quarter (Apr 1 - June 30)
2nd Quarter - Report
$75,000
Page 1 of 6  ·  55 filings Next
Filed By
FirmFilingsAmount
CURE SMA IN-HOUSE 43 $2,090,000
FAEGRE DRINKER BIDDLE & REATH LLP 12 $290,000
Issue Areas

Bills Mentioned in Filings